MYRIAD GENETICS INC

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of and (unaudited)

Condensed Consolidated Balance Sheets (unaudited)

	June 30,2025	December 31,2024
ASSETS
Current assets:
Cash and cash equivalents	$74.4	$102.4
Trade accounts receivable	137.0	121.2
Inventory	28.7	27.5
Prepaid taxes	14.3	16.4
Prepaid expenses and other current assets	29.9	30.5
Total current assets	284.3	298.0
Operating lease right-of-use assets	51.2	55.0
Property, plant, and equipment, net	113.0	117.4
Intangibles, net	170.1	262.4
Goodwill	51.6	286.3
Other assets	7.1	8.5
Total assets	$677.3	$1,027.6
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$30.9	$32.3
Accrued liabilities	100.6	119.0
Current maturities of operating lease liabilities	9.0	12.8
Current debt	59.4	—
Total current liabilities	199.9	164.1
Unrecognized tax benefits	1.2	32.7
Long-term debt	—	39.6
Noncurrent operating lease liabilities	86.2	87.9
Other long-term liabilities	1.9	2.2
Total liabilities	289.2	326.5
Commitments and contingencies
Stockholders’ equity:
Common stock, 93.1 and 91.3 shares outstanding at June 30, 2025 and December 31, 2024, respectively	0.9	0.9
Additional paid-in capital	1,474.7	1,457.8
Accumulated other comprehensive loss	(0.1)	(0.8)
Accumulated deficit	(1,087.4)	(756.8)
Total stockholders' equity	388.1	701.1
Total liabilities and stockholders’ equity	$677.3	$1,027.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.